Idiopathic pulmonary fibrosis: Treatment update
- First Online:
- Cite this article as:
- O’Connell, O.J., Kennedy, M.P. & Henry, M.T. Adv Therapy (2011) 28: 986. doi:10.1007/s12325-011-0066-5
Idiopathic pulmonary fibrosis (IPF) is the most common of the idiopathic interstitial pneumonias. Despite multiple recent clinical trials, there is no strong evidence supporting a survival advantage for any agent in the management of patients with IPF. The limited effectiveness of current treatment regimes has led to a search for novel therapies including antifibrotic strategies. This article reviews the evidence supporting the treatments currently used in the management of IPF.